Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046695 | 0.78 | TBXAS1 (0.44) | FDPSKMT2AMEN1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL23581665 | 0.76 | TBXAS1 (0.43) | FDPSKMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL10168063 | 0.74 | KMT2A (0.39) | FDPSKMT2AMEN1ALDH1A1 | |
| SCHEMBL2137686 | 0.74 | FDPS (0.49) | FDPSKMT2AMEN1SMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL9715312 | 0.73 | FDPS (0.47) | FDPSKMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL1075052 | 0.73 | FDPS (0.51) | FDPSKMT2AMEN1RAB9ATSHR | |
| SCHEMBL4877813 | 0.73 | FDPS (0.47) | FDPSKMT2AMEN1RAB9ATSHR | |
| SCHEMBL12475716 | 0.71 | MEN1 (0.37) | FDPSKMT2AMEN1L3MBTL1TSHR | |
| SCHEMBL8604105 | 0.71 | FDPS (0.43) | FDPSKMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL8451147 | 0.71 | FDPS (0.43) | FDPSKMT2AMEN1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840730-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2635582-B1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20160002703-A1 | IMIDAZO[1,2-alpha]PYRAZINE DERIVATIVES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-01-07 | — | — | US | disclosed |
| US-9139836-B2 | Imidazo[1,2-a]pyrazine derivatives | PROMEGA CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150064731-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2015-03-05 | — | — | US | disclosed |
| US-8809529-B2 | Imidazo[1,2-α]pyrazine derivatives | PROMEGA CORPORATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140227759-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140223590-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promego Corporation (US) | 2014-08-07 | — | — | US | disclosed |
| US-8669103-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| WO-2012061530-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | RNGTT, UPF1, NSUN2 | FDPS 1791/4885KMT2A 2803/4885MEN1 3202/4885 |
| US-20160002703-A1 | IMIDAZO[1,2-alpha]PYRAZINE DERIVATIVES | GLB1, NISCH, BOLA2; BOLA2B | FDPS 179/4885KMT2A 3183/4885MEN1 1366/4885 |
| US-20150064731-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | GLB1, LUC7L2, GUSB | FDPS 99/4885KMT2A 2786/4885MEN1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.